Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ908910-0,22
KB808808,50,31
PKN65,1765,180,00
Msft433,75434,12-1,46
Nokia3,3913,3950,79
IBM185,6186,250,22
Mercedes-Benz Group AG63,7763,79-0,96
PFE29,7929,870,37
19.07.2024 13:51:00
Indexy online
AD Index online
select
AD Index online
 

  • 18.07.2024
Cellectar Bioscn Rg (NASDAQ Cons)
Závěr k 18.7.2024 Změna (%) Změna (USD) Objem obchodů (ks)
2,63 0,38 0,01 241 618
Premarket19.07.2024 13:36:50
Poslední obchod Nákup / Prodej Změna (%) Změna (USD) Objem obchodů (ks)
- 2,63 2,79 - - -
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 19.07.2024
Popis společnosti
Obecné informace
Název společnostiCellectar Biosciences Inc
TickerCLRB
Kmenové akcie:Ordinary Shares
Kmenové akcie:Unit
RICCLRB.O
ISIN-
Prioritní akciePreference Shares Series C
Prioritní akcieConv. Pref. Shrs Series E
Prioritní akciePreference Shares Series A
Prioritní akciePreference Shares Series D
Prioritní akciePreference Shares Series D
Prioritní akciePreference Shares Series E2
Poslední známé roční výsledky31.12.2023
Poslední známé čtvrtletní výsledky31.03.2024
Počet zaměstnanců k 31.12.2023 20
Akcie v oběhu k 08.05.2024 35 848 924
MěnaUSD
Kontaktní informace
Ulice100 Campus Drive
MěstoFLORHAM PARK
PSČ07932
ZeměUnited States
Kontatní osobaMonique Kosse
Funkce kontaktní osobyIR Contact Officer
Telefon16 084 418 120
Fax16084418121
Kontatní telefon12 129 153 820

Business Summary: Cellectar Biosciences, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The Company, through phospholipid ether drug conjugate (PDC) delivery platform, is focused on developing PDCs that are designed to specifically target cancer cells. Its PDC platform possesses the potential for the discovery and development of cancer-targeting treatments, and it plans to develop PDCs both independently and through research and development collaborations. Its product pipeline includes iopofosine, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), preclinical PDC chemotherapeutic programs and multiple partnered PDC assets. Its Iopofosine is evaluated in the completed CLOVER-WaM Phase 2 pivotal study in patients with relapsed/refractory (r/r) Waldenstrom’s macroglobulinemia (WM).
Financial Summary: BRIEF: For the three months ended 31 March 2024, Cellectar Biosciences Inc revenues was not reported. Net loss increased from $8.6M to $21.6M. Higher net loss reflects General and administrative increase from $1.7M to $4.2M (expense), Reaserch and development increase of 11% to $7.3M (expense), General and administrative increase of 13% to $386K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.76 to -$0.74.
Odvětvová klasifikace
TRBC2012Pharmaceuticals (NEC)
RBSS2004Pharmaceuticals - Diversified
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSPharmaceutical Preparation Manufacturing
NAICSDrugs and Druggists' Sundries Merchant Wholesalers
NAICSResearch and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
NAICS2007Pharmaceutical Preparation Mfg
NAICS2007Drugs and Druggists' Sundries Merchant Wholesalers
NAICS2007Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
NAICS1997Pharmaceutical Preparation Manufacturing
NAICS1997Drug, Drug Proprietaries and Druggists' Sundries Wholesalers
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
SICPharmaceutical Preparations
SICPharmaceutical Preparations
SICDrugs/proprietaries/sundries
SICCommercial Physical Research



  • Poslední aktualizace: 19.07.2024
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
President, Chief Executive Officer, DirectorJames Caruso6415.06.201515.06.2015
Chief Financial Officer, Vice President, SecretaryChad Kolean5828.05.2014
Chief Operating OfficerJarrod Longcor5022.02.202215.07.2016
Senior Vice President - MedicalAndrei Shustov52
Chief Commercial OfficerShane Lea50